Copenhagen uPAR prostate cancer (CuPCa) database: protocol and early results

Solvej Lippert; Kasper D Berg; Gunilla Høyer-Hansen; Ida K Lund; Peter Iversen; Ib J Christensen; Klaus Brasso; Martin A Røder

doi:10.2217/bmm.15.114

Copenhagen uPAR prostate cancer (CuPCa) database: protocol and early results

Solvej Lippert, Kasper D Berg, Gunilla Høyer-Hansen, Ida K Lund, Peter Iversen, Ib J Christensen, Klaus Brasso, Martin A Røder

8 Citationer (Scopus)

Abstract

Urokinase plasminogen activator receptor (uPAR) plays a central role during cancer invasion by facilitating pericellular proteolysis. We initiated the prospective 'Copenhagen uPAR Prostate Cancer' study to investigate the significance of uPAR levels in prostate cancer (PCa) patients. Methods: Plasma samples and clinical data from patients with newly diagnosed PCa have been collected prospectively. The uPAR forms have been measured in plasma using time-resolved fluorescence immunoassays. Results: The level of intact uPAR(I-III) did not differ. Plasma uPAR(I-III) + uPAR(II-III) levels and uPAR(I) levels were significantly higher in hormone-naive and castrate-resistant patients compared with patients with localized disease (both: p < 0.0001). Conclusion: Our results show that cleaved uPAR forms are significantly increased in patients with advanced PCa.

Originalsprog	Engelsk
Tidsskrift	Biomarkers in Medicine
Vol/bind	10
Udgave nummer	2
Sider (fra-til)	209-16
Antal sider	8
ISSN	1752-0363
DOI	https://doi.org/10.2217/bmm.15.114
Status	Udgivet - feb. 2016

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.2217/bmm.15.114

Citationsformater

@article{0b01cfa401564d2eb1440aedf3b7ba96,

title = "Copenhagen uPAR prostate cancer (CuPCa) database: protocol and early results",

abstract = "Urokinase plasminogen activator receptor (uPAR) plays a central role during cancer invasion by facilitating pericellular proteolysis. We initiated the prospective 'Copenhagen uPAR Prostate Cancer' study to investigate the significance of uPAR levels in prostate cancer (PCa) patients. Methods: Plasma samples and clinical data from patients with newly diagnosed PCa have been collected prospectively. The uPAR forms have been measured in plasma using time-resolved fluorescence immunoassays. Results: The level of intact uPAR(I-III) did not differ. Plasma uPAR(I-III) + uPAR(II-III) levels and uPAR(I) levels were significantly higher in hormone-naive and castrate-resistant patients compared with patients with localized disease (both: p < 0.0001). Conclusion: Our results show that cleaved uPAR forms are significantly increased in patients with advanced PCa.",

keywords = "Journal Article, Research Support, Non-U.S. Gov't",

author = "Solvej Lippert and Berg, {Kasper D} and Gunilla H{\o}yer-Hansen and Lund, {Ida K} and Peter Iversen and Christensen, {Ib J} and Klaus Brasso and R{\o}der, {Martin A}",

year = "2016",

month = feb,

doi = "10.2217/bmm.15.114",

language = "English",

volume = "10",

pages = "209--16",

journal = "Biomarkers in Medicine",

issn = "1752-0363",

publisher = "Future Medicine Ltd.",

number = "2",

}

TY - JOUR

T1 - Copenhagen uPAR prostate cancer (CuPCa) database

T2 - protocol and early results

AU - Lippert, Solvej

AU - Berg, Kasper D

AU - Høyer-Hansen, Gunilla

AU - Lund, Ida K

AU - Iversen, Peter

AU - Christensen, Ib J

AU - Brasso, Klaus

AU - Røder, Martin A

PY - 2016/2

Y1 - 2016/2

N2 - Urokinase plasminogen activator receptor (uPAR) plays a central role during cancer invasion by facilitating pericellular proteolysis. We initiated the prospective 'Copenhagen uPAR Prostate Cancer' study to investigate the significance of uPAR levels in prostate cancer (PCa) patients. Methods: Plasma samples and clinical data from patients with newly diagnosed PCa have been collected prospectively. The uPAR forms have been measured in plasma using time-resolved fluorescence immunoassays. Results: The level of intact uPAR(I-III) did not differ. Plasma uPAR(I-III) + uPAR(II-III) levels and uPAR(I) levels were significantly higher in hormone-naive and castrate-resistant patients compared with patients with localized disease (both: p < 0.0001). Conclusion: Our results show that cleaved uPAR forms are significantly increased in patients with advanced PCa.

AB - Urokinase plasminogen activator receptor (uPAR) plays a central role during cancer invasion by facilitating pericellular proteolysis. We initiated the prospective 'Copenhagen uPAR Prostate Cancer' study to investigate the significance of uPAR levels in prostate cancer (PCa) patients. Methods: Plasma samples and clinical data from patients with newly diagnosed PCa have been collected prospectively. The uPAR forms have been measured in plasma using time-resolved fluorescence immunoassays. Results: The level of intact uPAR(I-III) did not differ. Plasma uPAR(I-III) + uPAR(II-III) levels and uPAR(I) levels were significantly higher in hormone-naive and castrate-resistant patients compared with patients with localized disease (both: p < 0.0001). Conclusion: Our results show that cleaved uPAR forms are significantly increased in patients with advanced PCa.

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.2217/bmm.15.114

DO - 10.2217/bmm.15.114

M3 - Journal article

C2 - 26764285

SN - 1752-0363

VL - 10

SP - 209

EP - 216

JO - Biomarkers in Medicine

JF - Biomarkers in Medicine

IS - 2

ER -

Copenhagen uPAR prostate cancer (CuPCa) database: protocol and early results

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater